In a large analysis of prescription patterns, Cleveland Clinic researchers find that fewer cancer patients than previously thought receive standard-of-care treatment for thrombosis.
Cleveland Clinic researcher among the team to find that many cancer patients at high risk for venous thromboembolism already have a blood clot before starting chemotherapy, suggesting benefit from anticoagulant prophylaxis.
Cleveland Clinic oncologist Alok Khorana, MD, discusses the appropriateness of cancer screenings in the wake of unprovoked thromboembolisms in a NEJM Editorial.
New analysis of the phase III CATCH trial of blood-thinning treatments identifies two clinical indicators for recurrent venous thromboembolism: tumor venous compression and hepatobiliary cancer.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
From a brand-new, 377,000-square-foot cancer building opening in 2017 to standardizing care, discover how Cleveland Clinic is changing the way it delivers colorectal cancer care.
Biliary cancers’ rarity, their often advanced stage at diagnosis and the scarcity of tissue biorepositories complicates treatment. Cleveland Clinic’s research and targeted treatment program aims to overcome these obstacles.
Results from Phase III CATCH trial add data to what was already a consensus-driven treatment option: low-molecular weight heparin.
Specialized team focuses on research, reducing costs